Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"AnGes","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anges to develop coronavirus vaccine with Osaka University","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed"},{"orgOrder":0,"company":"AnGes","sponsor":"Emendo Biotherapeutics","pharmaFlowCategory":"D","amount":"$61.0 million","upfrontCash":"Undisclosed","newsHeadline":"Emendo Biotherapeutics Raises $61 Million to Advance Next Generation Genome Editing Therapeutics","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"January 2020","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Undisclosed"},{"orgOrder":0,"company":"AnGes","sponsor":"Fresh Tracks Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AnGes Anoounces Collaboration Agreement with Brickell Biotech","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"AnGes","sponsor":"Er-Kim","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AnGes and Er-Kim Enter Into an Agreement for the Commercialization of Collategene\u00ae in Turkey","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"},{"orgOrder":0,"company":"AnGes","sponsor":"Emendo Biotherapeutics","pharmaFlowCategory":"D","amount":"$250.0 million","upfrontCash":"Undisclosed","newsHeadline":"EmendoBio Gene Editing Company Acquired by AnGes, Inc.","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical"},{"orgOrder":0,"company":"AnGes","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Japan's AnGes Begins Phase 2\/3 Clinical Trial Of DNA-Based COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"AnGes","sponsor":"Eiger BioPharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eiger BioPharmaceuticals and AnGes Announce Exclusive Partnership for Regulatory Approval and Commercialization of Zokinvy\u00ae (lonafarnib) in Japan","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved"},{"orgOrder":0,"company":"AnGes","sponsor":"Eiger BioPharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eiger and Partner, AnGes, Receive Approval for Zokinvy\u00ae (lonafarnib) for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2024","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by AnGes

    Menu

    AnGes

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              AnGes

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Eiger and Partner, AnGes, Receive Approval for Zokinvy® (lonafarnib) for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan

              Details:

              Zokinvy (lonafarnib) is a first-in-class farnesyltransferase inhibitor. It is approved for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies.

              Lead Product(s): Lonafarnib

              Therapeutic Area: Genetic Disease Product Name: Zokinvy

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Eiger BioPharmaceuticals

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 18, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              AnGes

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Eiger BioPharmaceuticals and AnGes Announce Exclusive Partnership for Regulatory Approval and Commercialization of Zokinvy® (lonafarnib) in Japan

              Details:

              Under the terms of the agreement, AnGes is responsible for obtaining and maintaining regulatory approval for Zokinvy (lonafarnib) in Japan and will be the exclusive partner for distribution and commercialization.

              Lead Product(s): Lonafarnib

              Therapeutic Area: Genetic Disease Product Name: Zokinvy

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Eiger BioPharmaceuticals

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership May 10, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              AnGes

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              EmendoBio Gene Editing Company Acquired by AnGes, Inc.

              Details:

              EmendoBio to operate as an independent subsidiary of AnGes with full access to AnGes’ global development resources to accelerate development and manufacturing capabilities for EmendoBio’s dual OMNI™ genome editing technology platforms.

              Lead Product(s): EMD-101

              Therapeutic Area: Genetic Disease Product Name: EMD-101

              Highest Development Status: Preclinical Product Type: Cell and Gene therapy

              Recipient: Emendo Biotherapeutics

              Deal Size: $250.0 million Upfront Cash: Undisclosed

              Deal Type: Acquisition December 15, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              AnGes

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Japan's AnGes Begins Phase 2/3 Clinical Trial Of DNA-Based COVID-19 Vaccine

              Details:

              The trials involve 500 people. A group of 250 people will be vaccinated twice with AG0302-COVID19, in an interval of two weeks; the second group of 250 people twice with an interval of four weeks.

              Lead Product(s): AG0302-COVID19

              Therapeutic Area: Infections and Infectious Diseases Product Name: AG0302-COVID19

              Highest Development Status: Phase II/ Phase III Product Type: Vaccine

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 08, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              AnGes

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              AnGes and Er-Kim Enter Into an Agreement for the Commercialization of Collategene® in Turkey

              Details:

              Under the terms of the agreement, Er-Kim will have the exclusive rights to commercialize Collategene® in Turkey after obtaining the necessary regulatory approvals.

              Lead Product(s): Beperminogene Perplasmid

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Collategene

              Highest Development Status: Approved Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Er-Kim

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement October 08, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              AnGes

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              AnGes Anoounces Collaboration Agreement with Brickell Biotech

              Details:

              AnGes is currently conducting Phase 1/2 clinical studies with its vaccine candidate in Japan, and the results from these studies will guide AnGes’ and Brickell’s global development efforts of this novel vaccine candidate.

              Lead Product(s): AG0302-COVID19

              Therapeutic Area: Infections and Infectious Diseases Product Name: AG0302-COVID19

              Highest Development Status: Phase I/ Phase II Product Type: Vaccine

              Partner/Sponsor/Collaborator: Fresh Tracks Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration September 08, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              AnGes

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Anges to develop coronavirus vaccine with Osaka University

              Details:

              The company is working on the developement of a prophylactic DNA vaccine for COVID-19 using plasmid DNA production technology.

              Lead Product(s): DNA vaccine

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Vaccine

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 05, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              AnGes

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Emendo Biotherapeutics Raises $61 Million to Advance Next Generation Genome Editing Therapeutics

              Details:

              The funding will accelerate novel OMNI gene editing platform into a broad therapeutic product pipeline.

              Lead Product(s): OMNI nuclease

              Therapeutic Area: Rare Diseases and Disorders Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

              Recipient: Emendo Biotherapeutics

              Deal Size: $61.0 million Upfront Cash: Undisclosed

              Deal Type: Series B Financing January 15, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY